Pharmacological effects and clinical application of serpatinib capsules

The efficacy of serpatinib capsules is outstanding in anti-cancer treatment, especially for cancer patients with specific genetic mutations, which provides a new treatment option.

Serpatinib capsule is a highly selective RET inhibitor that can precisely target cancer cells with RET gene fusion or mutation. This targeted therapy strategy not only improves the accuracy of treatment, but also reduces damage to normal cells, thereby reducing side effects during treatment.

In clinical trials, serpatinib capsules demonstrated impressive efficacy. For example, in a trial of thyroid cancer patients with RET mutations, up to 70% of patients treated with selpatinib showed signs of tumor shrinkage within 12 months. For other types of cancer such as non-small cell lung cancer (NSCLC), serpatinib has also shown significant tumor suppression effects, able to prolong patient survival and improve quality of life.

It is particularly worth mentioning that serpatinib capsules also demonstrated strong intracranial anti-tumor activity. This is undoubtedly important news for patients whose cancer has metastasized to the brain. Clinical trial data show that serpatinib can effectively cross the blood-brain barrier and attack cancer cells in the brain, thereby controlling the progression of the disease.

In addition to its remarkable efficacy, serpatinib capsules also have good safety and tolerability. Although some side effects may occur during use, such as increased AST and ALT enzymes, increased blood sugar, etc., these are controllable and their effects can be reduced through appropriate dosage adjustment and medical management.

References:

https://www.nejm.org/doi/full/10.1056/NEJMoa2005651